Croatia-headquartered Optimapharm acquires Swiss CRO

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/Kritchanut)
(Image: Getty/Kritchanut)

Related tags: Optimapharm, CRO, Clinical trial, acquisition

Optimapharm aims to become a leading mid-sized CRO in Europe and recently acquired the Switzerland-headquartered company Denothex as part of this goal.

According to the contract research organization (CRO) Optimapharm, the acquisition of Denothex strengthens its presence in the European market, specifically in France, Germany, Switzerland, Spain, and Italy.

Switzerland headquartered Denothex is a CRO with operations across Europe and Israel with a focus on biotechnology and medical devices in oncology.

Established in Zagreb, Croatia in 2006, Optimapharm​ aims to become “one of the leading mid-size CRO companies in Europe.”

The company currently has offices in 14 European countries and opened its first US location in June 2018​.

Optimapharm also acquired MKS Research in late 2017, at which time the company’s CEO Gordana Greguric Cicak told us​ he would continue looking for “good-quality acquisition targets.”

“Our goal is to consolidate the CRO market”​ in the Central and Eastern European Countries (CEE) as well as in South Eastern European (SEE) regions, he said.

Related topics: Clinical Development

Related news

Show more

Follow us

Featured Events

View more

Products

View more

Webinars